

Amoeba: US regulatory calendar update

Lyon (France), May 30, 2022 - 17h45 - AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, updates the regulatory calendar for both the biocide and biocontrol applications in the US.

Application for authorization of the biocide in the United States

The application for approval of the biocidal active substance, the living amoeba *Willaertia magna* C2c Maky, and biocidal products containing it, filed in April 2021 with the U.S. Environmental Protection Agency (U.S. EPA), is still under review. The conclusions were, according to the legal deadline announced by the authority, expected by mid-2022. The U.S. EPA has requested an extension of the assessment period: the conclusions of the assessment should now be available in the second half of 2022.

Application for authorization of the biocontrol in the United States

The application for approval of the biocontrol active substance, the lysate of *Willaertia magna* C2c Maky, and the biocontrol products containing it, filed in October 2020 with the U.S. Environmental Protection Agency (EPA), is still under review. The conclusions were, according to the legal deadline announced by the authority, expected by the end of May 2022. The U.S. EPA has requested an extension of the assessment period: the conclusions of the assessment should now be available in the second half of 2022.

About Amoéba :

Amoéba's ambition is to become the world leader in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (3). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (4) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The company is currently in the testing phase for biocidal and phytosanitary applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-nature.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

(4): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

Contacts:

Amoéba

Valérie FILIATRE
Deputy General Manager

+33 4 26 69 16 00

v.filiatre@amoeba-nature.com

Calyptus

Investor & Press Relations

Nicolas HELIN / Mathieu CALLEUX

+33 1 53 65 37 90 /91

amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.